Assistance Publique Hopitaux De Paris
Assistance Publique Hopitaux De Paris is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
Sponsor Swedish Orphan Biovitrum AB (publ)
- Start (EU)
- Latest update
- Estimated end
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Sponsor Cellectis
- Start (EU)
- Latest update
- Estimated end
BiFAST: A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line
Sponsor LYSARC
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
Sponsor LYSARC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Open label, single-center, cross-over randomized, relative bioavailability study comparing 4 new BF2.649 (pitolisant) tablet formulations versus the reference pitolisant (Wakix®) tablet formulation after single oral administrations in healthy male subjects.
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia
Sponsor Universitair Medisch Centrum Utrecht
- Start (EU)
- Latest update
- Estimated end
- Not reported
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated CLL (STAIR)"
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714
Sponsor Institut National De La Sante Et De La Recherche Medicale
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson's Disease
Sponsor Vivet Therapeutics
- Start (EU)
- Latest update
- Estimated end
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Assistance Publique Hopitaux De Paris?
The 2026-10-09 snapshot links Assistance Publique Hopitaux De Paris to 11 distinct CTIS trials. Recorded services include Laboratory services, Biological resources platform, Biological samples (blood and bone marrow aspirate) banking, centralized histological review, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Assistance Publique Hopitaux De Paris?
The most frequently recorded therapeutic areas are Haematological Malignancies, Nephrology. Recorded phases include Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Assistance Publique Hopitaux De Paris conducted?
The linked trials record locations in 16 countries, including France, Germany, Italy, Belgium, Spain. These are trial locations, not confirmed office locations or countries where Assistance Publique Hopitaux De Paris delivered services.
What can this page tell me about Assistance Publique Hopitaux De Paris's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Assistance Publique Hopitaux De Paris. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Assistance Publique Hopitaux De Paris